If youve been prescribed a weight loss medication or have been reading up on oral GLP-1s, you may be wondering how these options differ from the long-used injections
Retatrutide is not currently licensed in the UK and is not available to purchase
Two major clinical trials are the basis for most of what's known about these medications' weight-management effects: STEP 1 (68-week randomized study, adults without diabetes): semaglutide 2.4 mg produced an average loss of roughly 15% of body weight, versus about 2.4% with placebo, alongside a reduced-calorie diet and increased physical activity
Mounjaro, differing in its approach, utilizes tirzepatide as its active ingredient, targeting both GLP-1 and GIP receptors, which may, in some cases, enable more significant weight loss compared to Semaglutide GLP-1-based treatments
Accompanying gastrointestinal symptoms that suggest more serious conditions require medical assessment
Maintaining a rotation pattern, such as left abdomen one week, right abdomen the next, then left thigh, right thigh, keeps each site fresh
